BioLineRx Sets Shareholder Meeting for October 1
Ticker: BLRX · Form: 6-K · Filed: Aug 19, 2024 · CIK: 1498403
Sentiment: neutral
Topics: shareholder-meeting, corporate-governance
TL;DR
BioLineRx shareholder meeting set for Oct 1st. Be there.
AI Summary
BioLineRx Ltd. announced on August 19, 2024, that its Annual Meeting of Shareholders will take place on October 1, 2024, at 3:00 p.m. Israel time. The meeting will be held at the company's offices located at Modi'in Technology Park, 2 HaMa'ayan Street, Israel.
Why It Matters
This filing informs shareholders about the upcoming annual meeting where key decisions and elections will likely occur, impacting the company's future direction.
Risk Assessment
Risk Level: low — This is a routine corporate announcement regarding a shareholder meeting, with no immediate financial or operational risks disclosed.
Key Players & Entities
- BioLineRx Ltd. (company) — Registrant
- October 1, 2024 (date) — Date of Annual Meeting
- August 19, 2024 (date) — Filing Date
- Modi'in Technology Park, 2 HaMa'ayan Street, Israel (location) — Meeting Location
FAQ
When will BioLineRx Ltd. hold its Annual Meeting of Shareholders?
BioLineRx Ltd. will hold its Annual Meeting of Shareholders on October 1, 2024.
What time is the Annual Meeting scheduled for?
The meeting is scheduled for 3:00 p.m. Israel time.
Where will the Annual Meeting of Shareholders take place?
The meeting will be held at the Registrant's office, Modi'in Technology Park, 2 HaMa'ayan Street, Israel.
What form does BioLineRx Ltd. file its annual reports under?
BioLineRx Ltd. files its annual reports under Form 20-F.
Is this a report for the month of August 2024?
Yes, this is a Report of Foreign Private Issuer pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 for the month of August 2024.
Filing Stats: 276 words · 1 min read · ~1 pages · Grade level 9.5 · Accepted 2024-08-19 16:30:18
Filing Documents
- zk2431874.htm (6-K) — 11KB
- exhibit_99-1.htm (EX-99.1) — 154KB
- exhibit_99-2.htm (EX-99.2) — 18KB
- exhibit_99-3.htm (EX-99.3) — 37KB
- image00003.jpg (GRAPHIC) — 3KB
- image00004.jpg (GRAPHIC) — 7KB
- image00005.jpg (GRAPHIC) — 10KB
- 0001178913-24-002689.txt ( ) — 250KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BioLineRx Ltd. By: /s/ Philip A. Serlin Philip A. Serlin Chief Executive Officer Dated: August 19, 2024